Aarti Pharmalabs Ltd. (AARTIPHARM): Aarti Pharmalabs 52 Week High Streak: Second Straight Session Near Peak
- September 24, 2026
- Posted by: Harsh Piplani
- Category: News
Aarti Pharmalabs Ltd. (AARTIPHARM) has now traded within 2% of its 52-week high for its second straight session, with the streak showing a cumulative gain of 8%. The latest price action leaves the stock at Rs 954.2 against a recent peak of Rs 956.65, while the latest Univest data confirms the repeated-high pattern but does not establish a company-specific catalyst behind it.
The share price opened at Rs 930, touched a low of Rs 924.45 and moved up to Rs 956.65 in the current session, with turnover at Rs 1.38 crore and market capitalisation at Rs 8,012.01 crore. For readers, the repeated high matters more than a single-day move because it shows the stock has stayed close to its one-year high across more than one session, which can keep the market focused on valuation, earnings and sector context.
Aarti Pharmalabs 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 954.2 |
| Previous Close | Rs 940.1 |
| Today's Move | +Rs 14.1 (+1.5%) |
| Open | Rs 930 |
| High | Rs 956.65 |
| Low | Rs 924.45 |
| Turnover | Rs 1.38 crore |
| Market Capitalisation | Rs 8,012.01 crore |
Aarti Pharmalabs Ltd. (AARTIPHARM) traded at Rs 954.2 versus the previous close of Rs 940.1, a rise of 1.5%. The stock opened at Rs 930, reached a high of Rs 956.65 and touched a low of Rs 924.45.
Aarti Pharmalabs share price today is trading at Rs 954.2, up Rs 14.1 or 1.5% from the previous close of Rs 940.1. The session opened at Rs 930, moved between Rs 924.45 and Rs 956.65, and is now positioned near the upper end of that range. Turnover stands at Rs 1.38 crore, while the company’s market capitalisation is Rs 8,012.01 crore. For Aarti Pharmalabs stock news readers, this is the day’s factual setup that sits alongside the broader 52 Week High Streak. The market is not seeing a fresh breakout above the session peak in the numbers provided, but the price is still holding close to the year’s best zone. That keeps Aarti Pharmalabs NSE and BSE action firmly in focus for anyone tracking 52 Week High Stocks or Stocks At One Year High Today.
Aarti Pharmalabs 52 Week High Streak: Consecutive High Analysis
Aarti Pharmalabs 52 Week High Streak now runs for a second straight session, and the key point is the persistence of the move rather than a one-day spike. Across the streak, the stock has advanced 8%, which is the most useful figure for understanding how far the share price has travelled since the pattern began on 23 September 2026. The latest high of Rs 956.65 also gives readers a clear reference point for the current one-year peak zone. Because the event is defined as trading within 2% of the 52-week high, the latest reading shows the stock remains very close to that level rather than moving far away from it. This is why the Aarti Pharmalabs 52 Week High Streak is more informative than a single session headline: it shows the market has continued to keep the share price near the yearly high across back-to-back sessions.
What matters next is whether the price continues to stay inside that near-peak band. The repeated-high setup can remain in place even if the stock does not set a new one-year high immediately, and the latest numbers only confirm the pattern, not the reason behind it. For those searching for Aarti Pharmalabs 52 Week High For second straight session or Aarti Pharmalabs Consecutive 52 Week High, the essential detail is unchanged: the stock has stayed close to its annual peak for two sessions and has added 8% across that span.
What the Repeated 52-Week Highs Show
The repeated 52-week highs show that Aarti Pharmalabs is continuing to trade near the upper end of its yearly range, which can keep it on lists of Stocks Hitting 52 Week Highs and 52 Week High Stocks. The most important inference is not a catalyst story, because the latest Univest data does not confirm one, but a pattern story: the share price has remained near the 52-week peak for multiple sessions instead of being a one-off move.
For investors tracking Aarti Pharmalabs Share Price Update or Aarti Pharmalabs Stock Performance, the repeated-high pattern usually shifts attention toward the next set of figures that matter: earnings quality, margins, return ratios and valuation. The current market capitalisation of Rs 8,012.01 crore also places the company in a range where pricing expectations can react quickly to changes in business performance. In that sense, the streak is a market signal that the stock is being watched closely, even though the supplied facts do not tell us why the price has stayed elevated. That is why queries such as Is Aarti Pharmalabs Overbought are better handled through valuation and company fundamentals than through a price headline alone.
Aarti Pharmalabs Ltd. (AARTIPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 8,012.01 crore |
| P/E Ratio | 40x |
| P/B Ratio | 3.89x |
| ROE | 8.5% |
| ROCE | 10.77% |
| EPS | Rs 23.51 |
| Book Value Per Share | Rs 241.54 |
| Dividend Yield | 0.37% |
Aarti Pharmalabs Ltd. (AARTIPHARM) fundamental metrics show P/E 40x, P/B 3.89x, ROE 8.5%, ROCE 10.77%. These figures provide context only and are not a buy or sell signal.
Aarti Pharmalabs Ltd. has a market capitalisation of Rs 8012.01 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 40x, P/B at 3.89x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 8.5% and ROCE of 10.77%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 23.51, book value per share of Rs 241.54, dividend yield of 0.37%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.31x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 40x |
| Benchmark Median P/E | 28.31x |
| Benchmark Average P/E | 42.27x |
| Benchmark P/E Range | 0x to 762.66x |
| Company P/B Ratio | 3.89x |
| Benchmark Median P/B | 2.9x |
| Company ROE | 8.5% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 10.77% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 8,012.01 crore |
| Benchmark Median Market Cap | Rs 745.38 crore |
Aarti Pharmalabs Ltd. (AARTIPHARM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Aarti Pharmalabs Ltd. (AARTIPHARM) has a P/E ratio of 40x, which is above the benchmark median of 28.31x, a difference of +41.29%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Aarti Pharmalabs Ltd. (AARTIPHARM) has a ROE of 8.5%, which is below the benchmark median of 11.7%, a difference of -27.35%. Aarti Pharmalabs Ltd. (AARTIPHARM) has a ROCE of 10.77%, which is below the benchmark median of 13.61%, a difference of -20.87%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Supriya Lifescience Ltd. | SUPRIYA | 8,054.72 | 40.6 | 6.59 | 19.06 | 25.3 |
| Bliss GVS Pharma Ltd. | BLISSGVS | 7,341.06 | 54.42 | 6.01 | 12.11 | 17.4 |
| SYMBIOTEC PHARMALAB LTD | SYMBIOTEC | 7,204.72 | 62.1 | 4.55 | 11.22 | 12.41 |
| Procter & Gamble Health Ltd. | PGHL | 9,032.14 | 25.31 | 14.67 | 62.18 | 84.86 |
| Sanofi India Ltd. | SANOFI | 7,038.39 | 21.72 | 8.51 | 44.5 | 55.46 |
Aarti Pharmalabs Ltd. (AARTIPHARM) has a P/E ratio of 40x compared with the displayed peer median of 40.6x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 8.5% compares with a peer median of 19.06% across the companies shown in the table. ROCE stood at 10.77% versus the displayed peer median of 25.3%, providing a capital-efficiency comparison. Aarti Pharmalabs Ltd. (AARTIPHARM) has a market capitalisation of Rs 8,012.01 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Aarti Pharmalabs
- Aarti Pharmalabs 52 Week High Streak has now run for a second straight session.
- The stock has moved 8% across the streak, keeping the share price near its yearly peak.
- Current valuation stands at a P/E of 40 and a P/B of 3.89.
- ROE at 8.5% and ROCE at 10.77% sit below the industry medians.
- The company’s market capitalisation is Rs 8,012.01 crore, which keeps it on the radar of market update trackers.
About Aarti Pharmalabs
Aarti Pharmalabs Ltd. is part of the Pharmaceuticals & Drugs industry in Healthcare and is listed on NSE and BSE. The company’s market capitalisation is Rs 8,012.01 crore, and its valuation and return metrics place it within a competitive peer set that includes several well-followed pharmaceutical names. For readers tracking Aarti Pharmalabs Company News, the current streak adds a market focus point, but the long-term read still depends on business performance and earnings quality.
The latest numbers show revenue and profitability need to be interpreted together with margins, returns and valuation. That is why Aarti Pharmalabs Stock Analysis is best read as both a price story and a company fundamentals story, not one or the other.
Track Aarti Pharmalabs on Univest
Track Aarti Pharmalabs on Univest to follow the latest Aarti Pharmalabs Share Price Today, market cap updates, company news and 52 Week High Stocks coverage. The stock page keeps the focus on the same metrics readers use for Aarti Pharmalabs Stock Performance, peer comparison and sector analysis.
For a quick reference point, the current Aarti Pharmalabs 52 Week High Streak, valuation and sector context are all available in one place, making it easier to monitor the next move.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Aarti Pharmalabs 52 Week High Streak?
Ans. Aarti Pharmalabs 52 Week High Streak means the stock has traded within 2% of its 52-week high for a second straight session. The latest figures show the share price staying close to the one-year peak rather than moving away from it.
How many sessions has Aarti Pharmalabs stayed near its 52-week high?
Ans. According to latest Univest data, Aarti Pharmalabs has stayed within 2% of its 52-week high for two consecutive sessions. The streak began on 23 September 2026 and is still in progress.
What is the cumulative move across the Aarti Pharmalabs streak?
Ans. The cumulative move across the streak is 8%. That figure captures the full repeated-high pattern better than the day’s change alone and is the key streak-wide number for Aarti Pharmalabs Share Price Today readers.
Did Aarti Pharmalabs make a new 52-week high today?
Ans. The stock touched Rs 956.65 in the current session, which is the latest peak provided. The article does not state a fresh break above that level, only that the share price remained near the 52-week high zone.
What does the latest price action show for Aarti Pharmalabs?
Ans. Aarti Pharmalabs traded at Rs 954.2, above the previous close of Rs 940.1, after opening at Rs 930 and touching a low of Rs 924.45. The price stayed near the upper part of the session range.
Is a company-specific catalyst confirmed for the streak?
Ans. No company-specific catalyst is confirmed by the latest figures. The data confirm the repeated near-high price pattern, but they do not establish why the stock has stayed close to its 52-week peak.
How does Aarti Pharmalabs compare on valuation with peers?
Ans. Aarti Pharmalabs trades at a P/E of 40 and a P/B of 3.89. That places it above the industry median P/E and P/B, while some peers trade at even richer multiples and stronger return ratios.
What should investors monitor next in Aarti Pharmalabs stock?
Ans. Investors may watch whether the price continues to trade near the yearly high, how valuation compares with earnings performance, and whether return ratios improve. Those factors matter more than a one-session move when assessing the streak.
Track Aarti Pharmalabs Ltd. (AARTIPHARM) Share Price on Univest
Use Aarti Pharmalabs Ltd. (AARTIPHARM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
